5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Bradycardia O
with O
amiodarone O
coadministration O
: O
Serious O
symptomatic O
bradycardia O
may O
occur O
in O
patients O
taking O
amiodarone O
, O
particularly O
in O
patients O
also O
receiving O
beta O
blockers O
, O
or O
those O
with O
underlying O
cardiac O
comorbidities O
and/or O
advanced O
liver O
disease O
. O

Coadministration O
of O
amiodarone O
with O
HARVONI O
is O
not O
recommended O
. O

In O
patients O
without O
alternative O
, O
viable O
treatment O
options O
, O
cardiac O
monitoring O
is O
recommended O
. O

( O
5.1 O
, O
6.2 O
, O
7.2 O
) O
* O
Use O
with O
other O
drugs O
containing O
sofosbuvir O
, O
including O
SOVALDI O
, O
is O
not O
recommended O
( O
5.3 O
) O
5.1 O
Serious O
Symptomatic O
Bradycardia O
When O
Coadministered O
with O
Amiodarone O
Postmarketing O
cases O
of O
symptomatic O
bradycardia B-NonOSE_AE
, O
as O
well O
as O
fatal O
cardiac B-NonOSE_AE
arrest I-NonOSE_AE
and O
cases O
requiring O
pacemaker O
intervention O
, O
have O
been O
reported O
when O
amiodarone O
is O
coadministered O
with O
HARVONI O
. O

Bradycardia B-NonOSE_AE
has O
generally O
occurred O
within O
hours O
to O
days O
, O
but O
cases O
have O
been O
observed O
up O
to O
2 O
weeks O
after O
initiating O
HCV B-Not_AE_Candidate
treatment O
. O

Patients O
also O
taking O
beta O
blockers O
, O
or O
those O
with O
underlying O
cardiac B-Not_AE_Candidate
comorbidities I-Not_AE_Candidate
and/or O
advanced O
liver B-Not_AE_Candidate
disease I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
symptomatic B-NonOSE_AE
bradycardia I-NonOSE_AE
with O
coadministration O
of O
amiodarone O
. O

Bradycardia B-NonOSE_AE
generally O
resolved O
after O
discontinuation O
of O
HCV B-Not_AE_Candidate
treatment O
. O

The O
mechanism O
for O
this O
effect O
is O
unknown O
. O

Coadministration O
of O
amiodarone O
with O
HARVONI O
is O
not O
recommended O
. O

For O
patients O
taking O
amiodarone O
who O
have O
no O
other O
alternative O
, O
viable O
treatment O
options O
and O
who O
will O
be O
coadministered O
HARVONI O
: O
* O
Counsel O
patients O
about O
the O
risk O
of O
serious O
symptomatic O
bradycardia B-NonOSE_AE
* O
Cardiac O
monitoring O
in O
an O
in-patient O
setting O
for O
the O
first O
48 O
hours O
of O
coadministration O
is O
recommended O
, O
after O
which O
outpatient O
or O
self-monitoring O
of O
the O
heart O
rate O
should O
occur O
on O
a O
daily O
basis O
through O
at O
least O
the O
first O
2 O
weeks O
of O
treatment O
. O

Patients O
who O
are O
taking O
HARVONI O
who O
need O
to O
start O
amiodarone O
therapy O
due O
to O
no O
other O
alternative O
, O
viable O
treatment O
options O
should O
undergo O
similar O
cardiac O
monitoring O
as O
outlined O
above O
. O

Due O
to O
amiodarone O
's O
long O
half-life O
, O
patients O
discontinuing O
amiodarone O
just O
prior O
to O
starting O
HARVONI O
should O
also O
undergo O
similar O
cardiac O
monitoring O
as O
outlined O
above O
. O

Patients O
who O
develop O
signs O
or O
symptoms O
of O
bradycardia B-NonOSE_AE
should O
seek O
medical O
evaluation O
immediately O
. O

Symptoms O
may O
include O
near B-NonOSE_AE
- I-NonOSE_AE
fainting I-NonOSE_AE
or O
fainting B-NonOSE_AE
, O
dizziness B-NonOSE_AE
or O
lightheadedness B-NonOSE_AE
, O
malaise B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
excessive B-NonOSE_AE
tiredness I-NonOSE_AE
, O
shortness B-NonOSE_AE
of I-NonOSE_AE
breath I-NonOSE_AE
, O
chest B-NonOSE_AE
pains I-NonOSE_AE
, O
confusion B-NonOSE_AE
or O
memory B-NonOSE_AE
problems I-NonOSE_AE
[ O
See O
Adverse O
Reactions O
( O
6.2 O
) O
, O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.2 O
Risk O
of O
Reduced O
Therapeutic O
Effect O
Due O
to O
P-gp O
Inducers O
The O
concomitant O
use O
of O
HARVONI O
and O
P-gp O
inducers O
( O
e.g. O
, O
rifampin O
, O
St O
. O
John O
's O
wort O
) O
may O
significantly O
decrease O
ledipasvir O
and O
sofosbuvir O
plasma O
concentrations O
and O
may O
lead O
to O
a O
reduced O
therapeutic O
effect O
of O
HARVONI O
. O

Therefore O
, O
the O
use O
of O
HARVONI O
with O
P-gp O
inducers O
( O
e.g. O
, O
rifampin O
or O
St O
. O
John O
's O
wort O
) O
is O
not O
recommended O
[ O
see O
Drug O
Interactions O
( O
7.2 O
) O
] O
. O

5.3 O
Related O
Products O
Not O
Recommended O
The O
use O
of O
HARVONI O
with O
other O
products O
containing O
sofosbuvir O
( O
SOVALDI O
( O
r O
) O
) O
is O
not O
recommended O
. O

